BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B

Oxyphenbutazone

A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27)

300+ PubMed studies analyzed · 20 RCTs · Evidence Score: 45.8

Research Domains

Oxyphenbutazone has been studied across 15 research domains including 🔬 Inflammation, 🦴 Bone & Joint, 💊 Pain, ✨ Skin & Hair, 🧠 Focus & Attention. The primary research focus is 🔬 Inflammation with 16% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Oxyphenbutazone, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Nisoldipine
33 shared targets
Dinitrochlorobenzene
23 shared targets
Ciclopirox
20 shared targets
Vitamin
25 shared targets
Melphalan
21 shared targets
cycloheximide
25 shared targets
Azacitidine
21 shared targets
Azacitidine
21 shared targets
Methylene
30 shared targets
Oxymetholone
17 shared targets
Loading evidence profile...

This evidence profile for Oxyphenbutazone is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.